Publication date: Available online 4 November 2026 Source: The Journal of Pharmacology and Experimental Therapeutics Author(s): Dominique O. Farrera, Maxwell M. Maloney, Lucy Martinez-Guerrero, Solene Marie, Mina M. Alaaldin, Paige Lindberg, Kayla L. Frost, Stephen H. Wright, Nathan J. Cherrington
Metabolic dysfunction-associated steatohepatitis impairs renal anion transporter function and alters cefazolin pharmacokinetics in mice. // The Journal of Pharmacology and Experimental Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0022356526012632?dgcid=rss_sd_all
Metabolic dysfunction-associated steatohepatitis impairs renal anion transporter function and alters cefazolin pharmacokinetics in mice. The Journal of Pharmacology and Experimental Therapeutics. https://www.sciencedirect.com/science/article/pii/S0022356526012632?dgcid=rss_sd_all
“Metabolic dysfunction-associated steatohepatitis impairs renal anion transporter function and alters cefazolin pharmacokinetics in mice.” The Journal of Pharmacology and Experimental Therapeutics.
@article{article32405,
title = {Metabolic dysfunction-associated steatohepatitis impairs renal anion transporter function and alters cefazolin pharmacokinetics in mice},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0022356526012632?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...